These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 20412752)
1. [Human lung cancer: role of TLR7 and TLR8 in cell survival and chemoresistance]. Cherfils-Vicini J; Damotte D; Fridman WH; Sautès-Fridman C; Cremer I Med Sci (Paris); 2010 Apr; 26(4):435-7. PubMed ID: 20412752 [No Abstract] [Full Text] [Related]
2. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. Cherfils-Vicini J; Platonova S; Gillard M; Laurans L; Validire P; Caliandro R; Magdeleinat P; Mami-Chouaib F; Dieu-Nosjean MC; Fridman WH; Damotte D; Sautès-Fridman C; Cremer I J Clin Invest; 2010 Apr; 120(4):1285-97. PubMed ID: 20237413 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Cheng Q; Lee HH; Li Y; Parks TP; Cheng G Oncogene; 2000 Oct; 19(42):4936-40. PubMed ID: 11039911 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R Oncogene; 1999 Apr; 18(14):2357-65. PubMed ID: 10327056 [TBL] [Abstract][Full Text] [Related]
5. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Guo L; Zhou Y; Sun Y; Zhang F Eur J Cancer; 2010 Feb; 46(3):636-41. PubMed ID: 20004564 [TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. Hamm S; Rath S; Michel S; Baumgartner R J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448 [TBL] [Abstract][Full Text] [Related]
8. Terminal differentiation in a non-small-cell bronchopulmonary carcinoma correlates with increased expression of p53. Liscia E; Riou D; Slavoshian S; Boesch S; Lebert V; Tomasoni C; Dabouis G; Biard JF; Roussakis C Anticancer Res; 1996; 16(3A):1209-12. PubMed ID: 8702238 [TBL] [Abstract][Full Text] [Related]
9. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Chatterjee S; Crozet L; Damotte D; Iribarren K; Schramm C; Alifano M; Lupo A; Cherfils-Vicini J; Goc J; Katsahian S; Younes M; Dieu-Nosjean MC; Fridman WH; Sautès-Fridman C; Cremer I Cancer Res; 2014 Sep; 74(18):5008-18. PubMed ID: 25074614 [TBL] [Abstract][Full Text] [Related]
10. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R Cancer Res; 1999 Jun; 59(12):2829-33. PubMed ID: 10383141 [TBL] [Abstract][Full Text] [Related]
11. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. Liu X; Yue P; Zhou Z; Khuri FR; Sun SY J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759 [TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Laudanski J; Chyczewski L; Niklińska WE; Kretowska M; Furman M; Sawicki B; Nikliński J Neoplasma; 1999; 46(1):25-30. PubMed ID: 10355530 [TBL] [Abstract][Full Text] [Related]
13. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC). Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J Lung Cancer; 2010 Oct; 70(1):82-7. PubMed ID: 20064672 [TBL] [Abstract][Full Text] [Related]
14. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy. Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975 [TBL] [Abstract][Full Text] [Related]
15. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947 [TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637 [TBL] [Abstract][Full Text] [Related]
17. Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer. Mei H; Lin Z; Wang Y; Wu G; Song Y Neoplasma; 2014; 61(2):186-92. PubMed ID: 24299314 [TBL] [Abstract][Full Text] [Related]
18. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704 [TBL] [Abstract][Full Text] [Related]
19. [Responses to targeted therapies: lung cancer]. Brambilla E Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261 [No Abstract] [Full Text] [Related]
20. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. Dhandapani KM; Mahesh VB; Brann DW J Neurochem; 2007 Jul; 102(2):522-38. PubMed ID: 17596214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]